Business:
Computational chemistry platform to develop small molecule therapeutics
Drug notes:
Undisclosed programs RD infectious diseases, immunology conditions, oncology, rare & genetic diseases
About:
1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.
Executive Assistant Boston, MA|52 days ago
Scientist I, Small Molecule Assay Development (Bio... Boston, MA|100+ days ago
Scientist I, Assay Development for Small Molecule ... Boston, MA|100+ days ago
Scientist I, Antibody Assay Development (Biochemis... Boston, MA|100+ days ago
Head of Human Resources Boston, MA|100+ days ago
Director of Protein Therapeutics Boston, MA|100+ days ago
AI Research Scientist II Boston|100+ days ago
AI Research Scientist III Boston|100+ days ago
AI Research Scientist Boston|100+ days ago
Head of Biology Boston, MA|100+ days ago
Director of IT Boston, MA|100+ days ago
Chief of Staff - VP of Strategy and Operations Boston, MA|100+ days ago
Director of Business Development Boston, MA|100+ days ago